Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ISIS 14803, peginterferon alfa, ribavirin · 2 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| ISIS 14803 | DRUG | - |
| ISIS 14803, peginterferon alfa, ribavirin | DRUG | - |
Inclusion Criteria Patients must meet the following inclusion criteria during screening: * Age greater than or equal to 18 years. * Both males and females are eligible. All patients should be advised that there are no data on the possible reproductive (teratological) effects of ISIS 14803. Theref...
ISIS 14803 is an investigational small molecule being studied for the treatment of chronic hepatitis C virus infection. It was evaluated in clinical trials as a monotherapy and in combination with peginterferon alfa and ribavirin for patients who did not respond adequately to the two-drug regimen.
ISIS 14803 is being developed by Ionis Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol IONS. The company conducted clinical trials of the drug in patients with chronic hepatitis C virus infection.
ISIS 14803 is an investigational drug that has completed clinical trials. One trial was a Phase 2 study and another was a Phase 1 study, both in chronic hepatitis C. The drug is not approved and remains in clinical development, with no active trials currently listed.
ISIS 14803 has been studied in two completed clinical trials in the United States. NCT00035945 was a Phase 2 trial of ISIS 14803 administered intravenously in patients with chronic hepatitis C. NCT00062816 was a Phase 1 trial adding ISIS 14803 to peginterferon and ribavirin therapy in patients not responding adequately to the two drugs.
ISIS 14803 is an antisense oligonucleotide that targets the hepatitis C virus genome to inhibit viral replication. It was designed to bind to a specific sequence in the viral RNA, preventing the virus from producing proteins necessary for its replication and survival.